HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin Projects 20%-24% Growth In Q1 Despite China Regulatory Probe

This article was originally published in The Rose Sheet

Executive Summary

Analysts have faith in Nu Skin’s strategy, and future prospects, as it works with Chinese officials to resolve an investigation into its business practices in China. While the firm’s recent explosive growth is expected to fall off substantially in the first quarter of fiscal 2014 – to a more modest 20% to 24% – Nu Skin is confident that the steps it is taking in China “will make our long-term success more likely.”

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel